Goldsmith D J, Covic A
Renal Unit, Guy's Hospital, London, England, United Kingdom.
Kidney Int. 2001 Dec;60(6):2059-78. doi: 10.1046/j.1523-1755.2001.00040.x.
Cardiovascular disease is a major challenge to nephrologists, whether we deal with patients with pre-end-stage renal failure, on dialysis or after successful renal transplantation. It is the most common cause for death in patients with a functional allograft, and prevents many dialysis patients from being engrafted. Coronary artery disease is a diagnostic and therapeutic challenge, as it differs in some respects from that seen in non-uremic cohorts, and lacks much of the evidence-base on which therapeutic intervention rests. This review examines the experimental and clinical literature on cardiovascular disease in uremia, focusing on coronary artery disease. We focus on the incidence, presenting syndromes, screening tools, and interventions in the context of acute and chronic coronary syndromes. Recent evidence comparing coronary angioplasty, coronary artery stenting, and bypass surgery in subjects with renal failure is also reviewed. Coronary artery disease is more prevalent in uremia, more difficult to diagnose and less rewarding to treat compared to non-uremic subjects. Many more randomized trials are needed. In the absence of information from such trials, we advocate aggressive control of conventional and novel cardiovascular risk factors, and early intervention for symptomatic coronary disease.
心血管疾病对肾脏病学家来说是一项重大挑战,无论我们面对的是处于终末期肾衰竭前期的患者、正在接受透析治疗的患者还是肾移植成功后的患者。它是功能正常的移植肾患者最常见的死亡原因,并且使许多透析患者无法接受移植。冠状动脉疾病在诊断和治疗方面都具有挑战性,因为它在某些方面与非尿毒症人群中所见的情况不同,而且缺乏许多治疗干预所依据的证据基础。这篇综述审视了有关尿毒症患者心血管疾病的实验和临床文献,重点关注冠状动脉疾病。我们聚焦于急性和慢性冠状动脉综合征背景下的发病率、临床表现、筛查工具以及干预措施。同时也综述了近期有关肾衰竭患者冠状动脉血管成形术、冠状动脉支架置入术和搭桥手术比较的证据。与非尿毒症患者相比,冠状动脉疾病在尿毒症患者中更为普遍,更难诊断且治疗效果较差。还需要进行更多的随机试验。在缺乏此类试验信息的情况下,我们主张积极控制传统和新型心血管危险因素,并对有症状的冠状动脉疾病进行早期干预。